COG-AALL0631
| Clinical Trial Title | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
| Trial Status | Closed to Enrollment |
| Start Date | 02/26/2008 |
| Location | randall-childrens-hospital-at-legacy-emanuel |
| Trial Type | Pediatric Cancer (Oncology) |
| Specific Condition | Acute Lymphoblastic Leukemia (ALL) High Risk Infants |
| Description | This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia. |
| Eligibility Criteria | Patients must be enrolled on AALL08B1 (Classification Study) prior to enrollment on COG AALL0631 Age: <366 days of age at the time of diagnosis; for neonates in the first month of life, patients must be > 36 weeks gestational age at the time of diagnosis Patients must be newly diagnosed with Acute Lymphoblastic Leukemia (ALL) or Acute Undifferentiated Leukemia (AUL) Patients with T-cell ALL are eligible Patients with mature B-cell ALL or Acute Myelogenous Leukemia (AML) are not eligible Patients with Down syndrome are not eligible Patients receiving prior steroid therapy are eligible for study; any amount of steroid pretreatment will not affect initial Induction assignment as long as the patient meets all other eligibility criteria CNS status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment |
| IRB Number | |
| Notes | https://clinicaltrials.gov/ct2/show/NCT00557193 Study status is: |
| Principal Investigator | Janice Olson, MD |
| Contact Name | Children's Cancer and Blood Disorders Program |
| Contact Phone | (503) 276-9300 |
| Contact Fax | |
| Contact E-Mail |
